secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001651308-23-000152
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene's BRUKINSA receives positive NICE recommendation for CLL in UK
----------------------------------------------------------------------

- NICE final draft guidance recommends BRUKINSA for untreated CLL with 17p deletion or TP53 mutation, or when FCR/BR unsuitable, and for relapsed or refractory CLL.
- NICE found zanubrutinib cost-effective vs other BTK inhibitors, with lower incremental costs and more QALYs.
- Follows NICE's July 2022 recommendation for Waldenstrom's macroglobulinemia and Scottish Medicines Consortium approval on Oct 9, 2023.
- BRUKINSA approved in over 65 countries; global development program includes 5,000+ subjects in 29 countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/0001651308-23-000152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/bgne-20231020.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer